tetano
Editor, Senior Moderator
Front Microbiol. 2017 Jun 14;8:1086. doi: 10.3389/fmicb.2017.01086. eCollection 2017.
[h=1]Efficacy of Live-Attenuated H9N2 Influenza Vaccine Candidates Containing NS1 Truncations against H9N2 Avian Influenza Viruses.[/h] Chen S[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Zhu Y[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Yang D[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Yang Y[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Shi S[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Qin T[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Peng D[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Liu X[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H9N2 avian influenza virus is a zoonotic agent with a broad host range that can contribute genetic information to H5 or H7N9 subtype viruses, which are significant threats to both humans and birds. Thus, there is a great need for a vaccine to control H9N2 avian influenza. Three mutant viruses of an H9N2 virus A/chicken/Taixing/10/2010 (rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128) were constructed with different NS1 gene truncations and confirmed by western blot analysis. The genetic stability, pathogenicity, transmissibility, and host immune responses toward these mutants were evaluated. The mutant virus rTX-NS1-128 exhibited the most attenuated phenotype and lost transmissibility. The expression levels of interleukin 12 in the nasal and tracheal tissues from chickens immunized with rTX-NS1-128 were significantly upregulated on day 3 post-immunization and the IgA and IgG antibody levels were significantly increased on days 7, 14, and 21 post-immunization when compared to chickens that received an inactivated vaccine. rTX-NS1-128 also protected chickens from challenge by homologous and heterologous H9N2 avian influenza viruses. The results indicate that rTX-NS1-128 can be used as a potential live-attenuated vaccine against H9N2 avian influenza.
[h=4]KEYWORDS:[/h] H9N2; NS1; attenuation; avian influenza virus; vaccine
PMID: 28659900 PMCID: PMC5469905 DOI: 10.3389/fmicb.2017.01086
[h=1]Efficacy of Live-Attenuated H9N2 Influenza Vaccine Candidates Containing NS1 Truncations against H9N2 Avian Influenza Viruses.[/h] Chen S[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Zhu Y[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Yang D[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Yang Y[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Shi S[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Qin T[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Peng D[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Liu X[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] H9N2 avian influenza virus is a zoonotic agent with a broad host range that can contribute genetic information to H5 or H7N9 subtype viruses, which are significant threats to both humans and birds. Thus, there is a great need for a vaccine to control H9N2 avian influenza. Three mutant viruses of an H9N2 virus A/chicken/Taixing/10/2010 (rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128) were constructed with different NS1 gene truncations and confirmed by western blot analysis. The genetic stability, pathogenicity, transmissibility, and host immune responses toward these mutants were evaluated. The mutant virus rTX-NS1-128 exhibited the most attenuated phenotype and lost transmissibility. The expression levels of interleukin 12 in the nasal and tracheal tissues from chickens immunized with rTX-NS1-128 were significantly upregulated on day 3 post-immunization and the IgA and IgG antibody levels were significantly increased on days 7, 14, and 21 post-immunization when compared to chickens that received an inactivated vaccine. rTX-NS1-128 also protected chickens from challenge by homologous and heterologous H9N2 avian influenza viruses. The results indicate that rTX-NS1-128 can be used as a potential live-attenuated vaccine against H9N2 avian influenza.
[h=4]KEYWORDS:[/h] H9N2; NS1; attenuation; avian influenza virus; vaccine
PMID: 28659900 PMCID: PMC5469905 DOI: 10.3389/fmicb.2017.01086